



# The Value of Whole-Tumor Histogram and Texture Analysis Using Intravoxel Incoherent Motion in Differentiating Pathologic Subtypes of Locally Advanced Gastric Cancer

Huan-Huan Li<sup>1†</sup>, Bo Sun<sup>2†</sup>, Cong Tan<sup>3</sup>, Rong Li<sup>1</sup>, Cai-Xia Fu<sup>4</sup>, Robert Grimm<sup>5</sup>, Hui Zhu<sup>1\*</sup> and Wei-jun Peng<sup>1\*</sup>

# OPEN ACCESS

#### Edited by:

Luigi Marano, University of Siena, Italy

#### Reviewed by:

Giulio Bagnacci, University of Siena, Italy Ludovico Carbone, University of Siena, Italy

#### \*Correspondence:

Hui Zhu huizhu171717@163.com Wei-jun Peng pengweijun2017@.163.com

<sup>†</sup>These authors have contributed equally to this work and share first authorship

#### Specialty section:

This article was submitted to Gastrointestinal Cancers: Gastric & Esophageal Cancers, a section of the journal Frontiers in Oncology

> Received: 24 November 2021 Accepted: 20 January 2022 Published: 09 February 2022

#### Citation:

Li H-H, Sun B, Tan C, Li R, Fu C-X, Grimm R, Zhu H and Peng W-j (2022) The Value of Whole-Tumor Histogram and Texture Analysis Using Intravoxel Incoherent Motion in Differentiating Pathologic Subtypes of Locally Advanced Gastric Cancer. Front. Oncol. 12:821586. doi: 10.3389/fonc.2022.821586 <sup>1</sup> Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China, <sup>2</sup> Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, <sup>3</sup> Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China, <sup>4</sup> MR Applications Development, Siemens Shenzhen Magnetic Resonance Ltd, Shenzhen, China, <sup>5</sup> MR Applications Development, Siemens Healthcare, Erlangen, Germany

**Purpose:** To determine if whole-tumor histogram and texture analyses using intravoxel incoherent motion (IVIM) parameters values could differentiate the pathologic characteristics of locally advanced gastric cancer.

Methods: Eighty patients with histologically confirmed locally advanced gastric cancer who received surgery in our institution were retrospectively enrolled into our study between April 2017 and December 2018. Patients were excluded if they had lesions with the smallest diameter < 5 mm and severe image artifacts. MR scanning included IVIM sequences (9 b values, 0, 20, 40, 60, 100, 150,200, 500, and 800 s/mm<sup>2</sup>) used in all patients before treatment. Whole tumors were segmented by manually drawing the lesion contours on each slice of the diffusion-weighted imaging (DWI) images (with b=800). Histogram and texture metrics for IVIM parameters values and apparent diffusion coefficient (ADC) values were measured based on whole-tumor volume analyses. Then, all 24 extracted metrics were compared between well, moderately, and poorly differentiated tumors, and between different Lauren classifications, signet-ring cell carcinomas, and other poorly cohesive carcinomas using univariate analyses. Multivariate logistic analyses and multicollinear tests were used to identify independent influencing factors from the significant variables of the univariate analyses to distinguish tumor differentiation and Lauren classifications. ROC curve analyses were performed to evaluate the diagnostic performance of these independent influencing factors for determining tumor differentiation and Lauren classifications and identifying signet-ring cell carcinomas. The interobserver agreement was also conducted between the two observers for image quality evaluations and parameter metric measurements.

**Results:** For diagnosing tumor differentiation, the ADC<sub>median</sub>, pure diffusion coefficient median (Dslow<sub>median</sub>), and pure diffusion coefficient entropy (Dslow<sub>entropy</sub>) showed the greatest AUCs: 0.937, 0.948, and 0.850, respectively, and no differences were found between the three

February 2022 | Volume 12 | Article 821586

1

metrics, P>0.05). The 95th percentile perfusion factor (FP <sub>P95th</sub>) was the best metric to distinguish diffuse-type GCs vs. intestinal/mixed (AUC=0.896). The ROC curve to distinguish signet-ring cell carcinomas from other poorly cohesive carcinomas showed that the Dslow<sub>median</sub> had AUC of 0.738. For interobserver reliability, image quality evaluations showed excellent agreement (interclass correlation coefficient [ICC]=0.85); metrics measurements of all parameters indicated good to excellent agreement (ICC=0.65-0.89), except for the Dfast metric, which showed moderate agreement (ICC=0.41-0.60).

**Conclusions:** The whole-tumor histogram and texture analyses of the IVIM parameters based on the biexponential model provided a non-invasive method to discriminate pathologic tumor subtypes preoperatively in patients with locally advanced gastric cancer. The metric FP <sub>P95th</sub> derived from IVIM performed better in determining Lauren classifications than the mono-exponential model.

Keywords: gastric cancer, IVIM, pathological characterization, texture analysis, whole-tumor analysis

## INTRODUCTION

Li et al.

In China, gastric cancer (GC) has the second-highest cancer burden and the third most common cause of cancer-related deaths (with an age-standardized rate of incidence of 20.6 per 100,000 people, an age-standardized rate of mortality 15.9 per 100,000 population), and most patients are diagnosed at advanced disease stages (1). Patients presenting with locally advanced gastric cancer (LAGC) encounter problems associated with precise diagnoses and personalized treatment plans (2, 3) since tumor differentiation, Lauren classifications, and the presence of signet-ring cells can influence prognoses and treatment determinations (4-6). Lauren classifications are convenient and easy to implement and have good interobserver agreement (7). A recent study showed that the LAGC Lauren types correlated with perioperative chemotherapy responses (6). Endoscopic biopsies are invasive procedures prone to sampling errors due to the high heterogeneity of GCs; thus, the histopathology of tumor biopsies might not be consistent with those of whole-tumor resections (8, 9). Therefore, non-invasive imaging methods that could reliably predict the histopathologic characteristics of tumors could be useful.

Texture analysis is the method by which MRI and computed tomography (CT) radiologic data are processed using special software to extract texture features, which can quantitatively reflect pathologic information (10). CT remains the primary imaging modality in GC management owing to its relatively high accuracy rates and convenience (11). Several previous studies have shown that texture analyses from CT were useful for predicting GC prognoses and evaluating responses to neoadjuvant therapy (12–14), and some other studies have reported that preoperative CT texture analysis from omentum or primary tumors can help predict occult peritoneal metastases of advanced gastric cancers (15, 16). CT exposes patients to ionizing radiation and produces poor soft-tissue contrast. However, with technologic advancements, MRI temporal and spatial resolution has improved significantly, and its accuracy for assessing GC is similar to that of CT (17). Furthermore, MRI has good softtissue contrast and allows for repeated examinations owing to its non-ionizing radiation. It can also yield functional imaging features and has become a promising imaging technique for GC (11). However, applying texture analyses to MRI for GC diagnostics is less common (18); A few studies have found that apparent diffusion coefficient (ADC) first-order statistical metrics might be able to predict GC nodal status and are associated with perineural and vascular invasion (19, 20). Another study exploratory showed ADC histogram data from mono-exponential could reflect different histologic grades GC (21).

Based on diffusion-weighted imaging (DWI), Le Bihan et al. (22) proposed using intravoxel incoherent motion (IVIM) model to distinguish tissue perfusion and diffusion. IVIM is performed using bi-exponential curve fitting with multiple b-values and quantitative measurements with IVIM-derived parameters. Currently, this technique has been used for tumor grading, prognostic determinations, treatment monitoring, and distinguishing benign from malignant tumors (23, 24). However, it is rarer to use IVIM parameter texture analyses to evaluate GC in clinical research (25). Therefore, in this study, we aimed to investigate if IVIM whole-tumor histogram and texture analyses could be used to predict the pathologic features of LAGC.

## MATERIALS AND METHODS

#### **Patients**

The study was a retrospective, cross-sectional observational analysis. From April 2017 to December 2018, a total of 80 patients with LAGC were included. The study protocol was approved by our institutional review board. The inclusion criteria were as follows: a) patients who underwent surgery in our institution; b) patients with histologically confirmed GC; and c) patients who underwent

Abbreviations: ADC, apparent diffusion coefficient; AUC, area under the curve; Dfast, pseudo-diffusion coefficient; DWI, diffusion-weighted imaging; Dslow, pure molecular-based diffusion coefficient; FP, pseudo-diffusion perfusion factor; GC, gastric cancer; IVIM, intravoxel Incoherent Motion; ICC, interclass correlation coefficient; LAGC, locally advanced gastric cancer; P5th, 5th percentile; P95th, 95th percentile; PC, poorly cohesive carcinoma; ROC, receiver operating characteristic; SRC, signet-ring cell carcinoma.

preoperative MRI with IVIM sequences. Seventy-one patients were excluded: 1) patients had been treated before surgical interventions; 2) the time interval between MRI and surgery was  $\geq 2$  weeks; 3) patients failed to finish all MRI scan sequences; 4) had contraindications to raceanisodamine hydrochloride; 5) had small lesions (the smallest diameter < 5 mm); and 6) MRI images had severe artifacts (see **Figure 1**).

# **MRI Examinations**

Examinations were performed on a 3-Tesla MR scanner (MAGNETOM Skyra; Siemens Healthcare, Erlangen, Germany). We used an integrated body coil for excitation, with a dedicated 32channel spine coil and an 18-channel body coil for signal reception. To reduce artifacts from intestinal peristalsis, raceanisodamine hydrochloride (10 mg; Minsheng Pharmaceuticals, Hangzhou, China) was administered to patients intramuscularly 5–10 min before the MR examinations, unless contraindicated. Patients fasted for more than 6 h to ensure the stomach was empty and then drank 500-800 ml water immediately before the MR examination to distend the stomach.

IVIM acquisitions were obtained before administering contrast medium, using a single-shot echo-planar imaging sequence (SS-EPI) with diffusion gradients of 9 b-values (0, 20, 40, 60, 100, 150, 200, 500, 800 s/mm2), and a 3D-diagonal diffusion mode was applied.

Other routine sequences included axial T1-weighted imaging (T1WI; in-phase and out-of-phase), axial T2-weighted imaging (T2WI), and axial contrast-enhanced imaging using volumetric



signet-ring cell carcinoma; PC, poorly cohesive carcinoma

interpolated breath-hold examinations (VIBEs). The detailed scanning parameters are shown in **Table 1**.

## **MR** Image and Data Analyses

MR image quality was rated by two radiologists (with 5 and 10 years of abdominal diagnosis experience, respectively) according to a five-point Likert-type scale (1 = very poor, 2 = poor, 3 = moderate, 4 = good, and 5 = excellent), with a higher score indicating a better assessment.

The IVIM parameters (Dslow, pure molecular-based diffusion coefficient; Dfast, pseudo-diffusion coefficient; and FP, pseudodiffusion perfusion factor) and ADC values were calculated using the Body Diffusion Toolbox (prototype software, Siemens Healthcare, Erlangen, Germany) based on all acquired b-values. Then, the IVIM parameter maps, ADC maps, and DWI with b=800 were imported into prototypic MR Multiparametric Analysis software (Siemens Healthcare, Erlangen, Germany). The two radiologists drew regions of interest (ROIs) manually on DWI images (with b=800), using contrast-enhanced images as references. ROIs were drawn along cancer lesion margins (excluding the areas with the highest and lowest signals to avoid partial-volume effects). After ROIs were drawn around whole tumors, based on IVIM parameters and ADC values, five histogram-derived texture metrics (median, P95th, P5th, skewness, kurtosis) and one second-order texture metric (entropy) were generated. Skewness and kurtosis reflect histogram shapes and measure parameter distribution asymmetries, and entropy represents variations in the parameter distributions of interest (26).

To evaluate interobserver agreement for image quality and data measurements, image quality scores and data analysis results of the two radiologists were tested.

## **Histopathologic Examinations**

Histopathologic analyses were performed by a pathologist (with 10 years of clinical experience) who was blinded to IVIM

parameter measurements. Tissue sections were stained with a hematoxylin and eosin (HE) stain according to routine procedures. Tumor differentiation, Lauren classifications, and the identification of poorly cohesive carcinomas (PCs) and signet-ring cell carcinomas (SRCs) on histology were evaluated and recorded according to the World Health Organization (WHO) classification (27) and Chinese national standard for GC diagnosis and treatment (28).

# **Statistical Analyses**

The Shapiro-Wilk test and QQ plots were used to check the normality of the continuous variable distributions. The twosample t-test or Mann-Whitney test was used to detect the metrics differences between the SRCs and other PCs. We used the one-way ANOVA and Kruskal-Wallis test to compare these metrics among the three differentiation degrees and the three Lauren classifications. Since many variables existed, logistic regression and multicollinear tests were adopted to screen out independent influencing factors for tumor differentiation and the Lauren classification. Then, screened variables were subjected to receiver operating characteristic (ROC) curve analyses, and the results were guaranteed to have practical significance due to the elimination of confounding factors. The ROC curve diagnostic accuracy was interpreted as low (area under the curve [AUC]=0.50-0.70), moderate (AUC=0.70-0.90), or high (AUC>0.90) (29). The interobserver agreement between the two radiologists was evaluated with the interclass correlation coefficient (ICC) test, which was interpreted as having a poor (ICC=0.00-0.20), fair (ICC=0.21-0.40), moderate (ICC=0.41-0.60), good 0.61-0.80, and 0.81-1.00, excellent correlations (30).

A P-value of <0.05 was considered statistically significant. ROC curve parameter comparisons were assessed using MedCalc software version 19.6.0, and other statistical analyses were performed using SPSS software version 23.0.

TABLE 1   IVIM and routine sequence parameters.							
Parameter	IVIM Sequence	T1-weighted IP and OP Sequence	T2-weighted Sequence	T1-weighted VIBE Sequence			
Repetition time (msec)/echo time (msec)	5700/54	120/1.4 and 2.74	3500/83	3.9/1.89			
b values (sec/mm <sup>2</sup> )	0, 20, 40, 60, 100, 150, 200, 500, 800	_	_	_			
Slice thickness (mm)	5	3.5	4	3.5			
Slice gap (mm)	1	0.7	0.8	0.7			
Acquisition matrix	128 × 128	320 × 240	256 × 256	320 × 240			
Field of view (mm <sup>2</sup> )	380 × 380	380 × 310	380 × 380	380 × 310			
Acquisition time	3min and 9s	26s	3min and 15s	17s×3(30,60,90s)			
Flip angle value	Excitation 90°	70°	91°	9°			
	Refocusing 180°	_	_	_			
Parallel imaging factor	2	_	_	_			
Echo-planar imaging factor	115	_	_	_			
No. of signals acquired	Sequentially according to b values: 2, 2, 2, 2, 3, 4, 4, 4, 6.	2	4	1			

IP, in-phase; IVIM, intravoxel incoherent motion; OP, out-of-phase; and VIBE, volumetric interpolated breath-hold examination.

The acquisition planes are all axial imaging.

#### The IVIM Histogram and Texture Analysis in GC

# RESULTS

## The Study Population and Interobserver Agreement

Eighty patients were finally included in the study. The average age of the patients (58 men and 22 women) was 60.7 years (range, 28–89 years). Tumors were located in the gastric cardia and fundus in 27 cases, the gastric body in 24 cases, and the gastric antrum in 29 cases. Most tumors in the cardia and fundus involved in the study were not confined to cardia or fundus, and there was no clear demarcation between the two areas. Therefore, we did not distinguish them among anatomical subtypes. For more detailed patient characteristics, see **Table 2**.

The interobserver agreement for image quality evaluations was excellent (the ICC was 0.85), so we adopted results from the first reader. Of the recruited patients, IVIM images from 26 patients were rated as 5 points (excellent), 32 patients as 4 points (good), 18 patients as 3 points (moderate), and 4 patients as 2 points (poor). We observed the IVIM image artifacts of 4 patients with 2 points, but the artifacts were on the abdominal wall and did not affect the gastric lesion conspicuity. The interobserver agreement for ADC, Dslow, and FP measurements was good to excellent (ICC=0.65-

TABLE 2 | Baseline and demographic data in 80 patients.

Patient sex           No. of men         58 (72.5%)           No. of women         22 (27.5%)           Age (y)         60.7 (28-89)           Tumor location         24 (30.0%)           Gastric body         24 (30.0%)           Gastric body         24 (30.0%)           Gastric antrum         29 (36.3%)           Tumor volume (cm <sup>3</sup> )         43.2 (3.4-200.7)           Tumor smallest diameter (mm)         16.9 (6.0-65.0)           Pathologic findings         7           T staging         7           T2         12 (15.0%)           T3         36 (45.0%)           T4a         32 (40.0%)           N staging         20 (25%)           N2         23 (28.75%)           N3         18 (22.5%)           Tumor differentiated         21 (26.2%)           Moderately differentiated         21 (26.2%)      <	Characteristics	Value
No. of men         58 (72.5%)           No. of women         22 (27.5%)           Age (y)         60.7 (28-89)           Tumor location         24 (30.0%)           Gastric body         24 (30.0%)           Gastric and fundus         27 (33.7%)           Gastric body         24 (30.0%)           Gastric antrum         29 (36.3%)           Tumor volume (cm <sup>3</sup> )         43.2 (3.4-200.7)           Tumor smallest diameter (mm)         16.9 (6.0-65.0)           Pathologic findings         7           T2         12 (15.0%)           T3         36 (45.0%)           T4a         32 (40.0%)           N staging         18 (22.5%)           N1         20 (25%)           N2         23 (28.75%)           N3         18 (22.5%)           Tumor differentiated         21 (26.2%)           Moderately differentiated         47 (58.8%)           Lauren classification         11           Intestinal type         32 (40.0%)           Mixed type         24 (30.0%)           Diffuse type         24 (30.0%)           Diffuse type         24 (30.0%)           Diffuse type         24 (30.0%)           Non-PCs <t< td=""><td>Patient sex</td><td></td></t<>	Patient sex	
No. of women         22 (27.5%)           Age (y)         60.7 (28-89)           Tumor location         27 (33.7%)           Gastric body         24 (30.0%)           Gastric body         24 (30.0%)           Gastric body         29 (36.3%)           Tumor volume (cm <sup>3</sup> )         43.2 (3.4-200.7)           Tumor smallest diameter (mm)         16.9 (6.0-65.0)           Pathologic findings         7           T2         12 (15.0%)           T3         36 (45.0%)           T4a         32 (40.0%)           N Staging         19 (23.75%)           N1         20 (25%)           N2         23 (28.75%)           N3         18 (22.5%)           Tumor differentiated         21 (26.2%)           Moderately differentiated         21 (26.2%)           Moderately differentiated         47 (58.8%)           Lauren classification         11           Intestinal type         32 (40.0%)           Mixed type         24 (30.0%)           Diffuse type         24 (30.0%)           Diffuse type         24 (30.0%)           Diffuse type         54 (67.5%)           PCs         26 (32.5%)	No. of men	58 (72.5%)
Age (y)         60.7 (28-89)           Tumor location         27 (33.7%)           Gastric body         24 (30.0%)           Gastric body         24 (30.0%)           Gastric body         29 (36.3%)           Tumor volume (cm <sup>3</sup> )         43.2 (3.4-200.7)           Tumor smallest diameter (mm)         16.9 (60-65.0)           Pathologic findings         7           T2         12 (15.0%)           T3         36 (45.0%)           T4a         32 (40.0%)           N staging         20 (25%)           N2         23 (28.75%)           N3         18 (22.5%)           Tumor differentiated         21 (26.2%)           Moderately differentiated         12 (15.0%)           Poorly differentiated         47 (58.8%)           Lauren classification         11           Intestinal type         32 (40.0%)           Mixed type         24 (30.0%)           Diffuse type         24 (30.0%)           Diffuse type         24 (30.0%)           Diffuse type         54 (67.5%)           PCs         26 (32.5%)	No. of women	22 (27.5%)
Tumor location         27 (33.7%)           Gastric body         24 (30.0%)           Gastric body         24 (30.0%)           Gastric antrum         29 (36.3%)           Tumor volume (cm <sup>3</sup> )         43.2 (3.4-200.7)           Tumor smallest diameter (mm)         16.9 (6.0-65.0)           Pathologic findings         7           T staging         7           T2         12 (15.0%)           T3         36 (45.0%)           T4a         32 (40.0%)           N         staging           NO         19 (23.75%)           N1         20 (25%)           N2         23 (28.75%)           N3         18 (22.5%)           Tumor differentiated         21 (26.2%)           Moderately differentiated         12 (15.0%)           Poorly differentiated         47 (58.8%)           Lauren classification         11           Intestinal type         32 (40.0%)           Mixed type         24 (30.0%)           Diffuse type         54 (67.5%)	Age (y)	60.7 (28-89)
Cardia and fundus         27 (33.7%)           Gastric body         24 (30.0%)           Gastric antrum         29 (36.3%)           Tumor volume (cm <sup>3</sup> )         43.2 (3.4-200.7)           Tumor smallest diameter (mm)         16.9 (6.0-65.0)           Pathologic findings         7           T2         12 (15.0%)           T3         36 (45.0%)           T4a         32 (40.0%)           N staging         20 (25%)           N0         19 (23.75%)           N1         20 (25%)           N2         23 (28.75%)           N3         18 (22.5%)           Tumor differentiated         21 (26.2%)           Moderately differentiated         12 (15.0%)           Poorly differentiated         47 (58.8%)           Lauren classification         1           Intestinal type         32 (40.0%)           Mixed type         24 (30.0%)           Diffuse type         24 (30.0%)           Histologic types         24 (30.0%)           Non-PCs         54 (67.5%)           PCs         26 (32.5%)	Tumor location	
Gastric body         24 (30.0%)           Gastric antrum         29 (36.3%)           Tumor volume (cm <sup>3</sup> )         43.2 (3.4-200.7)           Tumor smallest diameter (mm)         16.9 (6.0-65.0)           Pathologic findings         7           Tz         12 (15.0%)           T3         36 (45.0%)           T4a         32 (40.0%)           N staging         7           NO         19 (23.75%)           N1         20 (25%)           N2         23 (28.75%)           N3         18 (22.5%)           Tumor differentiated         21 (26.2%)           Moderately differentiated         12 (15.0%)           Poorly differentiated         47 (58.8%)           Lauren classification         1           Intestinal type         32 (40.0%)           Mixed type         24 (30.0%)           Diffuse type         24 (30.0%)           Diffuse type         24 (30.0%)           Diffuse type         54 (67.5%)           PCs         26 (32.5%)	Cardia and fundus	27 (33.7%)
Gastric antrum         29 (36.3%)           Tumor volume (cm <sup>3</sup> )         43.2 (3.4-200.7)           Tumor smallest diameter (mm)         16.9 (6.0-65.0)           Pathologic findings         7           T2         12 (15.0%)           T3         36 (45.0%)           T4a         32 (40.0%)           N staging         20 (25%)           N0         19 (23.75%)           N1         20 (25%)           N2         23 (28.75%)           N3         18 (22.5%)           Tumor differentiation         21 (26.2%)           Moderately differentiated         12 (15.0%)           Poorly differentiated         12 (15.0%)           Intestinal type         32 (40.0%)           Mixed type         24 (30.0%)           Diffuse type         24 (30.0%)           Histologic types         24 (30.0%)           Non-PCs         54 (67.5%)           PCs         26 (32.5%)	Gastric body	24 (30.0%)
Tumor volume (cm <sup>3</sup> )       43.2 (3.4-200.7)         Tumor smallest diameter (mm)       16.9 (6.0-65.0)         Pathologic findings       7         T staging       12 (15.0%)         T3       36 (45.0%)         T4a       32 (40.0%)         N staging       19 (23.75%)         N1       20 (25%)         N2       23 (28.75%)         N3       18 (22.5%)         Tumor differentiated       21 (26.2%)         Moderately differentiated       12 (15.0%)         Poorly differentiated       47 (58.8%)         Lauren classification       11         Intestinal type       32 (40.0%)         Mixed type       24 (30.0%)         Diffuse type       24 (30.0%)         Histologic types       54 (67.5%)         PCs       26 (32.5%)         SRCs       12 (15.0%)	Gastric antrum	29 (36.3%)
Tumor smallest diameter (mm)         16.9 (6.0-65.0)           Pathologic findings         T           T staging         12 (15.0%)           T3         36 (45.0%)           T4a         32 (40.0%)           N staging         19 (23.75%)           N1         20 (25%)           N2         23 (28.75%)           N3         18 (22.5%)           Tumor differentiation         21 (26.2%)           Moderately differentiated         21 (26.2%)           Moderately differentiated         47 (58.8%)           Lauren classification         11           Intestinal type         32 (40.0%)           Mixed type         24 (30.0%)           Diffuse type         24 (30.0%)           Histologic types         54 (67.5%)           PCs         26 (32.5%)           SRCs         12 (15.0%)	Tumor volume (cm <sup>3</sup> )	43.2 (3.4-200.7)
Pathologic findings         T staging         T2       12 (15.0%)         T3       36 (45.0%)         T4a       32 (40.0%)         N staging       19 (23.75%)         N0       19 (23.75%)         N1       20 (25%)         N2       23 (28.75%)         N3       18 (22.5%)         Tumor differentiation       21 (26.2%)         Moderately differentiated       21 (26.2%)         Moderately differentiated       12 (15.0%)         Poorly differentiated       47 (58.8%)         Lauren classification       11         Intestinal type       32 (40.0%)         Mixed type       24 (30.0%)         Diffuse type       24 (30.0%)         Histologic types       24 (30.0%)         PCs       26 (32.5%)         SRCs       12 (15.0%)	Tumor smallest diameter (mm)	16.9 (6.0-65.0)
T staging         T2       12 (15.0%)         T3       36 (45.0%)         T4a       32 (40.0%)         N staging       32 (40.0%)         N staging       20 (25%)         N1       20 (25%)         N2       23 (28.75%)         N3       18 (22.5%)         Tumor differentiated       21 (26.2%)         Moderately differentiated       21 (26.2%)         Moderately differentiated       12 (15.0%)         Poorly differentiated       47 (58.8%)         Lauren classification       11         Intestinal type       32 (40.0%)         Mixed type       24 (30.0%)         Diffuse type       24 (30.0%)         Histologic types       54 (67.5%)         PCs       26 (32.5%)         SRCs       12 (15.0%)	Pathologic findings	
T2       12 (15.0%)         T3       36 (45.0%)         T4a       32 (40.0%)         N staging       19 (23.75%)         N0       19 (23.75%)         N1       20 (25%)         N2       23 (28.75%)         N3       18 (22.5%)         Tumor differentiated       21 (26.2%)         Moderately differentiated       12 (15.0%)         Poorly differentiated       47 (58.8%)         Lauren classification       11         Intestinal type       32 (40.0%)         Mixed type       24 (30.0%)         Diffuse type       24 (30.0%)         Histologic types       54 (67.5%)         PCs       26 (32.5%)         SRCs       12 (15.0%)	T staging	
T3       36 (45.0%)         T4a       32 (40.0%)         N staging       19 (23.75%)         N0       19 (23.75%)         N1       20 (25%)         N2       23 (28.75%)         N3       18 (22.5%)         Tumor differentiation       21 (26.2%)         Well-differentiated       21 (26.2%)         Moderately differentiated       12 (15.0%)         Poorly differentiated       47 (58.8%)         Lauren classification       11         Intestinal type       32 (40.0%)         Mixed type       24 (30.0%)         Diffuse type       24 (30.0%)         Histologic types       24 (30.0%)         Non-PCs       54 (67.5%)         PCs       26 (32.5%)         SRCs       12 (15.0%)	T2	12 (15.0%)
T4a       32 (40.0%)         N staging       19 (23.75%)         N0       19 (23.75%)         N1       20 (25%)         N2       23 (28.75%)         N3       18 (22.5%)         Tumor differentiation       21 (26.2%)         Well-differentiated       21 (26.2%)         Moderately differentiated       12 (15.0%)         Poorly differentiated       47 (58.8%)         Lauren classification       11         Intestinal type       32 (40.0%)         Mixed type       24 (30.0%)         Diffuse type       24 (30.0%)         Histologic types       54 (67.5%)         PCs       26 (32.5%)         SRCs       12 (15.0%)	Т3	36 (45.0%)
N staging           N0         19 (23.75%)           N1         20 (25%)           N2         23 (28.75%)           N3         18 (22.5%)           Tumor differentiation         21 (26.2%)           Well-differentiated         21 (26.2%)           Moderately differentiated         12 (15.0%)           Poorly differentiated         47 (58.8%)           Lauren classification         11           Intestinal type         32 (40.0%)           Mixed type         24 (30.0%)           Diffuse type         24 (30.0%)           Histologic types         54 (67.5%)           PCs         26 (32.5%)           SRCs         12 (15.0%)	T4a	32 (40.0%)
NO         19 (23.75%)           N1         20 (25%)           N2         23 (28.75%)           N3         18 (22.5%)           Tumor differentiation         21 (26.2%)           Well-differentiated         21 (26.2%)           Moderately differentiated         12 (15.0%)           Poorly differentiated         47 (58.8%)           Lauren classification         11           Intestinal type         32 (40.0%)           Mixed type         24 (30.0%)           Diffuse type         24 (30.0%)           Histologic types         54 (67.5%)           PCs         26 (32.5%)           SRCs         12 (15.0%)	N staging	
N1         20 (25%)           N2         23 (28.75%)           N3         18 (22.5%)           Tumor differentiation         7           Well-differentiated         21 (26.2%)           Moderately differentiated         12 (15.0%)           Poorly differentiated         47 (58.8%)           Lauren classification         11           Intestinal type         32 (40.0%)           Mixed type         24 (30.0%)           Diffuse type         24 (30.0%)           Histologic types         7           Non-PCs         54 (67.5%)           PCs         26 (32.5%)           SRCs         12 (15.0%)	NO	19 (23.75%)
N2         23 (28.75%)           N3         18 (22.5%)           Tumor differentiation         21 (26.2%)           Moderately differentiated         21 (26.2%)           Moderately differentiated         12 (15.0%)           Poorly differentiated         47 (58.8%)           Lauren classification         11           Intestinal type         32 (40.0%)           Mixed type         24 (30.0%)           Diffuse type         24 (30.0%)           Histologic types         54 (67.5%)           PCs         26 (32.5%)           SRCs         12 (15.0%)	N1	20 (25%)
N3         18 (22.5%)           Tumor differentiation         21 (26.2%)           Moderately differentiated         21 (25.0%)           Poorly differentiated         12 (15.0%)           Poorly differentiated         47 (58.8%)           Lauren classification         11           Intestinal type         32 (40.0%)           Mixed type         24 (30.0%)           Diffuse type         24 (30.0%)           Histologic types         24 (30.0%)           Non-PCs         54 (67.5%)           PCs         26 (32.5%)           SRCs         12 (15 0%) <td>N2</td> <td>23 (28.75%)</td>	N2	23 (28.75%)
Tumor differentiationWell-differentiated21 (26.2%)Moderately differentiated12 (15.0%)Poorly differentiated47 (58.8%)Lauren classification1Intestinal type32 (40.0%)Mixed type24 (30.0%)Diffuse type24 (30.0%)Histologic types467.5%)PCs26 (32.5%)SRCs12 (15.0%)	N3	18 (22.5%)
Well-differentiated         21 (26.2%)           Moderately differentiated         12 (15.0%)           Poorly differentiated         47 (58.8%)           Lauren classification         1           Intestinal type         32 (40.0%)           Mixed type         24 (30.0%)           Diffuse type         24 (30.0%)           Histologic types         24           Non-PCs         54 (67.5%)           PCs         26 (32.5%)           SRCs         12 (15.0%)	Tumor differentiation	
Moderately differentiated         12 (15.0%)           Poorly differentiated         47 (58.8%)           Lauren classification         1           Intestinal type         32 (40.0%)           Mixed type         24 (30.0%)           Diffuse type         24 (30.0%)           Histologic types         24           Non-PCs         54 (67.5%)           PCs         26 (32.5%)           SRCs         12 (15.0%)	Well-differentiated	21 (26.2%)
Poorly differentiated         47 (58.8%)           Lauren classification         32 (40.0%)           Intestinal type         32 (40.0%)           Mixed type         24 (30.0%)           Diffuse type         24 (30.0%)           Histologic types         24           Non-PCs         54 (67.5%)           PCs         26 (32.5%)           SRCs         12 (15 0%)	Moderately differentiated	12 (15.0%)
Lauren classification         32 (40.0%)           Intestinal type         32 (40.0%)           Mixed type         24 (30.0%)           Diffuse type         24 (30.0%)           Histologic types         24 (30.0%)           Non-PCs         54 (67.5%)           PCs         26 (32.5%)           SRCs         12 (15.0%)	Poorly differentiated	47 (58.8%)
Intestinal type         32 (40.0%)           Mixed type         24 (30.0%)           Diffuse type         24 (30.0%)           Histologic types         7           Non-PCs         54 (67.5%)           PCs         26 (32.5%)           SRCs         12 (15.0%)	Lauren classification	
Mixed type         24 (30.0%)           Diffuse type         24 (30.0%)           Histologic types         24 (30.0%)           Non-PCs         54 (67.5%)           PCs         26 (32.5%)           SRCs         12 (15.0%)	Intestinal type	32 (40.0%)
Diffuse type         24 (30.0%)           Histologic types         24           Non-PCs         54 (67.5%)           PCs         26 (32.5%)           SBCs         12 (15.0%)	Mixed type	24 (30.0%)
Histologic types           Non-PCs         54 (67.5%)           PCs         26 (32.5%)           SBCs         12 (15.0%)	Diffuse type	24 (30.0%)
Non-PCs         54 (67.5%)           PCs         26 (32.5%)           SBCs         12 (15.0%)	Histologic types	
PCs 26 (32.5%) SBCs 12 (15.0%)	Non-PCs	54 (67.5%)
SBCs 12 (15 0%)	PCs	26 (32.5%)
12 (10.070)	SRCs	12 (15.0%)
Other PCs 14 (17.5%)	Other PCs	14 (17.5%)

Continuous data are shown as means, with ranges in brackets. Categorical data are expressed as numbers of patients, with percentages in brackets.

T staging, tumor staging; N staging, lymph node staging; SRCs, signet-ring cell carcinomas; PC, poorly cohesive carcinoma.

0.89), and the agreement for Dfast measurements was moderate (ICC=0.41-0.60; see **Table 3**).

# Histograms and Texture Metrics of IVIM Parameters for Tumor Differentiation

The median, P5th, and P95th values of the ADC, Dslow, and FP parameters were higher in the well/moderately differentiated GCs compared with those in the poorly differentiated GCs(all total P-values <0.05, except the P-value for Dslow<sub>P5th</sub>). The skewness, kurtosis, and entropy values of the ADC, Dslow, and FP parameters were lower in the well/moderately differentiated GCs compared with those in the poorly differentiated GCs (all total P-values <0.05, except P-value for ADC<sub>kurtosis</sub>). For the Dfast parameter, none of the metric values were different among the three differentiation degrees (P >0.05); see **Table E1** (online). **Table E1** also shows the paired comparisons among the three differentiation degrees. Representative cases from the two groups are shown in **Figures 2**, **3**.

ADC<sub>median</sub>, Dslow<sub>median</sub>, Dslow<sub>entropy</sub>, and FP<sub>P95th</sub> were screened out as independent influencing factors for tumor differentiation (the cutoff values for distinguishing the well/ moderately differentiated and poorly differentiated GCs were  $1601.50 \times 10^{-6}$  mm<sup>2</sup>/s,  $1356.50 \times 10^{-6}$  mm<sup>2</sup>/s, 3.16, and 63.15%, respectively). In ROC curve analyses, we found Dslow<sub>median</sub> had the largest AUC of 0.948 (P<0.001) with an accuracy of 91.3%, sensitivity of 89.4%, and specificity of 93.9%; however, these values were not statistically different from those of ADC<sub>median</sub> and Dslow<sub>entropy</sub> (P>0.05; see **Table 4** and **Figure 4**).

#### Histograms and Texture Metrics of IVIM Parameters for Lauren Classifications

Except for Dfast metrics,  $Dslow_{P5th}$ , and  $FP_{entropy}$ , other metrics were statistically different among the three Lauren classifications. The median, P5th, and P95th values of the ADC, Dslow, and FP parameters were higher in the intestinal/mixed types compared with those in the diffuse-types (all total P-values <0.05, except the P-value for Dslow<sub>P5th</sub>). The skewness, kurtosis, and entropy values of the ADC, Dslow, and FP parameters were lower in the intestinal/mixed types compared with those in the diffusetypes(all total P-values <0.05, except the P-value for FP<sub>entropy</sub>); see **Table E2** (online). **Table E2** also shows the paired comparisons among the different Lauren classification groups.

We further screened the independent influencing factors for the different Lauren classification groups, including  $ADC_{median}$ ,  $Dslow_{median}$ ,  $Dslow_{entropy}$ , and  $FP_{P95th}$ . We found that  $FP_{P95th}$ had the largest AUC of 0.896 (P<0.001) with an accuracy of 77.5%, sensitivity of 95.8%, and specificity of 69.6%, with no statistical difference between the other three metrics (see **Table 5** and **Figure 5**).

## Histograms and Texture Metrics of IVIM Parameters for Differentiating Signet-Ring Cell Carcinomas from the Other Poorly Cohesive Types

All SRC and other PC metrics were compared using univariate analyses. The  ${\rm Dslow}_{\rm median}$  value was the only metric that showed

Variable metrics	ADC	Dslow	Dfast	FP
Median	0.82 [0.74,0.88]	0.81 [0.72,0.87]	0.60 [0.43,0.72]	0.88 [0.82,0.92]
P5th	0.85 [0.77,0.90]	0.88 [0.82,0.92]	0.58 [0.42,0.71]	0.89 [0.83,0.93]
P95th	0.78 [0.68,0.85]	0.74 [0.62,0.82]	0.49 [0.30,0.64]	0.84 [0.76,0.89]
Skewness	0.73 [0.61,0.82]	0.74 [0.63,0.83]	0.44 [0.24,0.60]	0.76 [0.65,0.84]
Kurtosis	0.79 [0.69,0.86]	0.88 [0.82,0.92]	0.45 [0.26,0.61]	0.84 [0.77,0.90]
Entropy	0.65 [0.51,0.76]	0.72 [0.60,0.81]	0.41 [0.21,0.58]	0.78 [0.67,0.85]

TABLE 3 | Interobserver agreement for parameters measurements assessed by the interclass correlation coefficient.

Data are interobserver correlation coefficients, with 95% confidence intervals in brackets.

ADC, apparent diffusion coefficient; Dslow, pure molecular-based diffusion coefficient; Dfast, pseudo-diffusion coefficient; FP, pseudo-diffusion factor given as a percentage; P5th, 5th percentile; and P95th, 95th percentile.

statistical differences between the two groups, with the SRC values being less than those of the other PC types (P <0.05); see **Table E3** (online). In the ROC analyses, the Dslow<sub>median</sub> had an AUC of 0.738, with an accuracy of 70.4%, sensitivity of 75.0%, and specificity of 71.4%; see **Table 6** and **Figure 6**.

## DISCUSSION

Our research focused on analyzing histogram and texture characteristics of IVIM parameters for LAGC with different pathological subtypes. IVIM imaging has the advantage of simultaneously obtaining diffusion and perfusion information without a co-registration processing step and the administration of contrast media (31). Many studies have reported its application in rectal tumors, concluding that IVIM parameters reflected histologic changes after treatment. Studies have also shown that IVIM parameters are associated with tumor differentiation and clinical staging (32-35). However, clinical studies looking at IVIM in patients with GC have not been commonly reported, although a few animal studies have examined chemotherapeutic efficacies (36, 37). An initial study reported the use of IVIM parameters to assess GC histotypes, but single-slice ROIs rather than whole-tumor volumetric measurements were used, and histograms and texture analyses were not applied (38). SRC is a rare type of adenocarcinoma characterized by signet-ring cells that secrete large amounts of mucin and displace the nucleus to the cell periphery (39). This cancer type is insensitive to chemoradiotherapy and has a poor prognosis in advanced stages (40). In 2010, the WHO classification defined PC as isolated or small aggregates of discohesive carcinoma cells with an infiltrative pattern, including SRCs and other cell types (27, 41).. There have only been a few previously published MRI studies on SRC, especially with respect to the difference between SRCs and other PC types. In this study, we explored the value of whole-tumor histogram and texture features for IVIM parameters in identifying GC differentiation, Lauren types, and SRC carcinomas according to ROC curve analysis.

For tumor differentiation, we found that the diffusion parameter metrics, ADC<sub>median</sub>, Dslow<sub>median</sub>, and Dslow<sub>entropy</sub>, showed better diagnostic performance as independent influencing factors for distinguishing poorly differentiated from the well/moderately differentiated GCs (see Figure 4). The ADC<sub>median</sub> and Dslow<sub>median</sub> values of poorly differentiated tumors were significantly lower than those of the well/ moderately differentiated tumors. These findings were similar to a previously reported study, which showed that restricted water motion in malignant tumors was associated with tumor differentiation (21). In addition, the Dslow<sub>entropy</sub> value of poorly differentiated tumors was higher than that of well/ moderately differentiated tumors, suggesting that poorly differentiated tumors have more radiologic heterogeneity/ variability. As a perfusion parameter, the diagnostic performance of FP<sub>P95th</sub> for tumor differentiation was not too bad, although the AUC was smaller than that of ADC<sub>median</sub>, Dslow<sub>median</sub>, and Dslow<sub>entropy</sub>. In our study, the FP<sub>P95th</sub> in the poorly differentiated tumor was significantly lower than that of well/moderately differentiated tumors, which could indicate that lower FP values are related to the hypoperfusion of blood caused by fewer normal glandular structures in poorly differentiated tumors (35).

Lauren classifications can reflect the biological aggressiveness of GC, in which diffuse-type GCs display a diffusely invasive growth pattern with a worse prognosis than intestinal/mixed-type (5). We found the perfusion parameter metric,  $FP_{P95th}$ , had the best diagnostic efficiency for discriminating diffuse-type GCs from intestinal/mixed-type GCs (see Figure 5). The FP<sub>P95th</sub> values of the diffuse-type GCs were significantly lower than those of the intestinal/mixed-type GCs, which suggests that the diffuse-type GC FP histograms were less frequent at the high end of the FP values compared with intestinal/mixed-type GC FP histograms. We previously showed that diffuse-type GCs have a less glandular appearance than intestinal/mixed GCs (5), which suggests that the lower FP values of diffuse-type GCs might be due to the hypoperfusion of blood caused by fewer normal glandular structures. Diffuse-type GCs also had higher Dslow<sub>entropy</sub> values than intestinal/mixed-type GCs, indicating that the diffuse-type GCs have more radiologic heterogeneity/variability on the Dslow maps. A previous study reported that the ADC values from a mono-exponential model correlated with the GC Lauren classifications (42). Our research indicated that the FP<sub>P95th</sub> metric performed better than ADC in determining Lauren classifications, demonstrating the advantage of using IVIM multi-parametric analyses from the biexponential model over using parametric analyses from the mono-exponential model.



FIGURE 2 | A case of gastric antrum cancer. The colored regions in (A–D) represent the lesion parameters maps; (a–d) show histogram parameter distributions for the whole tumor (ADC, Dslow, Dfast, and FP presenting sequentially). (E) Shows the contour of the region of interest (ROI). (F) A photomicrograph of an HE stained tissue section demonstrating a moderately differentiated adenocarcinoma.





8

Variable metrics	Cutoff	Accuracy	Sensitivity	Specificity	PPV	NPV	AUC	P-value
ADC <sub>median</sub>	1601.50 <sup>a</sup>	90.0%	91.5%	87.9%	91.5%	87.9%	0.937 [0.874-0.985]	<0.001
Dslow <sub>median</sub>	1356.50 <sup>a</sup>	91.3%	89.4%	93.9%	95.5%	86.1%	0.948 [0.860-0.979]	< 0.001
Dslow <sub>entropy</sub>	3.16	78.8%	74.5%	84.8%	87.5%	70.0%	0.850 [0.749-0.918]	< 0.001
FP <sub>P95th</sub>	63.15%	76.3%	80.9%	69.7%	79.2%	71.9%	0.803 [0.699-0.883]	< 0.001

TABLE 4 | The diagnostic performance of the independent influencing factors for the well/moderately differentiated vs. poorly differentiated GC.

Numbers in brackets are 95% confidence intervals (95% Cl).

PPV, Positive predictive value; NPV, Negative predictive value; AUC, area under the curve; ADC, apparent diffusion coefficient; Dslow, pure molecular-based diffusion coefficient; FP, pseudo-diffusion factor given as a percentage; and P95th, 95th percentile.

a, 10<sup>-6</sup>mm<sup>2</sup>/s.

No differences (P >0.05) were detected by paired comparisons between ADC<sub>median</sub>, Dslow<sub>median</sub>, and Dslow<sub>entropy</sub>.



**FIGURE 4** | Receiver operating characteristic (ROC) curves of screened independent influencing factors that could distinguish poorly differentiated from well/moderately differentiated GCs.  $ADC_{median}$ ,  $Dslow_{median}$ , and  $Dslow_{entropy}$  show good diagnostic performance, with AUCs of 0.937, 0.948, and 0.850, respectively. Comparisons among the four metrics determined that these values were significantly different (P <0.05), although no differences (P >0.05) were detected when paired comparisons among the  $ADC_{median}$ ,  $Dslow_{median}$ , and  $Dslow_{entropy}$  values were performed.

Our research found that the Dslow<sub>median</sub> values of the SRCs were lower than those of other PC types, providing moderate

diagnostic efficacies for distinguishing the two types (see **Figure 6**). The parameter Dslow from the biexponential model, which separates perfusion effects, might reflect the true diffusion state within lesions better than ADC from the mono-exponential model (23, 31). In our study,  $Dslow_{median}$  value was the only metric that showed statistical differences between the SRCs and other PC types, and which had greater AUC values than  $ADC_{median}$  in determining tumor differentiation and Lauren classifications. However, the differences were not statistically significant and could have been caused by the relatively small sample size of some groups and the difficulty of including additional b-values in clinical practice.

Our study used whole-tumor analysis for IVIM parameter metric measurements. This whole-tumor analysis reduced intratumoral heterogeneity influences on the measurements and provided more reproducible and reliable data than single-slice ROI analyses (33, 43). In this research, all parameter measurements had good or excellent interobserver reproducibility except for Dfast, which showed greater measurement susceptibility with moderate agreement.

There were several limitations to this study. First, early GC lesions are small and susceptible to motion artifacts and partial-volume averaging; thus, our research included only patients with LAGC (the smallest diameter of lesions  $\geq 5$  mm). Second, we used water as the negative contrast agent to fill the stomach cavity; however, gas-liquid levels sometimes appeared near the lesions, leading to susceptibility artifacts. Future prospective studies will develop a more robust acquisition method and a special gastric filling contrast agent to minimize susceptibility artifacts. Third, there were slightly fewer cases in the diffuse group, but according to the EPV (events per variable) principle proposed by

TABLE 5 | The diagnostic performance of the independent influencing factors for the intestinal/mixed vs. diffuse-type GC.

Variable metrics	Cutoff	Accuracy	Sensitivity	Specificity	PPV	NPV	AUC	P value
ADC <sub>median</sub>	1626.50 <sup>a</sup>	62.5%	91.7%	50.0%	44.0%	93.3%	0.747 [0.637-0.838]	<0.001
Dslow <sub>median</sub>	1437.50 <sup>a</sup>	60.0%	95.8%	44.6%	42.6%	96.2%	0.762 [0.653-0.850]	< 0.001
Dslow <sub>entropy</sub>	3.16	68.8%	75.0%	66.1%	48.6%	86.0%	0.755 [0.646-0.844]	< 0.001
FP <sub>P95th</sub>	61.15%	77.5%	95.8%	69.6%	57.5%	97.5%	0.896 [0.829-0.963]	< 0.001

Numbers in brackets are 95% confidence intervals.

PPV, Positive predictive value; NPV, Negative predictive value; AUC, area under the curve; ADC, apparent diffusion coefficient; Dslow, pure molecular-based diffusion coefficient; FP, pseudo-diffusion factor given as a percentage; and P95th, 95th percentile.

 $a = 10^{-6} mm^2/s.$ 

No differences (P >0.05) were detected by paired comparisons between ADC<sub>median</sub>, Dslow<sub>median</sub>, and Dslow<sub>entropy</sub>.



![](_page_9_Figure_3.jpeg)

TABLE 6 | The diagnostic performance of Dslow<sub>median</sub> for discriminating SRCs and other poorly cohesive carcinomas.

Variable metrics	Cutoff	Accuracy	Sensitivity	Specificity	PPV	NPV	AUC	P value
Dslow <sub>median</sub>	1041.00 <sup>a</sup>	70.4%	75.0%	71.4%	69.2%	76.9%	0.738 [0.537-0.939]	0.020

Numbers in brackets are 95% confidence intervals

PPV, Positive predictive value; NPV, Negative predictive value; AUC, area under the curve SRCs, Signet-ring cell carcinomas; ADC, apparent diffusion coefficient; and Dslow, pure molecular-based diffusion coefficient.

 $a = 10^{-6} mm^2/s.$ 

No differences (P >0.05) were detected by paired comparisons between ADC<sub>median</sub> and Dslow<sub>median</sub>.

Vittinghoff et al. (44), the sample size was sufficient for the analyses. In addition, the sample sizes of patients with SRC and other PC were small, so for these individuals, we only performed univariate analyses. Given that SRC is less common, our univariate analytic results have some significance.

Despite these limitations, our study showed the novel advantages of IVIM multi-parameter histogram and texture analyses for GC research based on the biexponential model. Moreover, IVIM provided an additional perfusion parameter, FP, which demonstrated greater potential for determining Lauren classifications than ADC from the mono-exponential model.

# DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

# **ETHICS STATEMENT**

The study is approved by Fudan University Shanghai Cancer Center Institutional Review Board. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

# **AUTHOR CONTRIBUTIONS**

W-JP and HZ conceived this idea and managed the research project, H-HL and BS designed this study, MRI data acquisition was performed by H-HL and RL, Statistical analysis was performed by H-HL and HZ, BS was contributed to clinical data interpretation, CT performed pathological analysis. C-XF

and RG provided software analysis methods. All authors contributed to the article and approved the submitted version.

# FUNDING

This work was supported by the National Natural Science Foundation of China (grant number 81902436) and the Science and Technology Commission of Shanghai Municipality (grant number STCSM18411953000).

## REFERENCES

- Qiu HB, Cao SM, Xu RH. Cancer Incidence, Mortality, and Burden in China: A Time-Trend Analysis and Comparison With the United States and United Kingdom Based on the Global Epidemiological Data Released in 2020. *Cancer Commun (Lond)* (2021) 41:1037–48. doi: 10.1002/cac2.12197
- Mocan L. Surgical Management of Gastric Cancer: A Systematic Review. J Clin Med (2021) 10:2557. doi: 10.3390/jcm10122557
- Tokunaga M, Sato Y, Nakagawa M, Aburatani T, Matsuyama T, Nakajima Y, et al. Perioperative Chemotherapy for Locally Advanced Gastric Cancer in Japan: Current and Future Perspectives. *Surg Today* (2020) 50:30–7. doi: 10.1007/s00595-019-01896-5
- Alshehri A, Alanezi H, Kim BS. Prognosis Factors of Advanced Gastric Cancer According to Sex and Age. World J Clin Cases (2020) 8:1608–19. doi: 10.12998/wjcc.v8.i9.1608
- Chen YC, Fang WL, Wang RF, Liu CA, Yang MH, Lo SS, et al. Clinicopathological Variation of Lauren Classification in Gastric Cancer. *Pathol Oncol Res* (2016) 22:197–202. doi: 10.1007/s12253-015-9996-6
- Zurlo IV, Basso M, Strippoli A, Calegari MA, Orlandi A, Cassano A, et al. Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren's Classification in Pan-Cancer Analysis Era? *Cancers (Basel)* (2020) 12:1749. doi: 10.3390/cancers12071749
- Yu Y. Evaluation of Traditional Pathological Classification at Molecular Classification Era for Gastric Cancer. *Chin J Gastrointest Surg* (2014) 17:18–20.
- Tae CH, Lee JH, Min BH, Kim KM, Rhee PL, Kim JJ. Negative Biopsy After Referral for Biopsy-Proven Gastric Cancer. *Gut Liver* (2016) 10:63–8. doi: 10.5009/gnl14281
- Yan H, Li M, Cao L, Chen H, Lai H, Guan Q, et al. A Robust Qualitative Transcriptional Signature for the Correct Pathological Diagnosis of Gastric Cancer. J Transl Med (2019) 17:63. doi: 10.1186/s12967-019-1816-4
- Hainc N, Stippich C, Stieltjes B, Leu S, Bink A. Experimental Texture Analysis in Glioblastoma: A Methodological Study. *Invest Radiol* (2017) 52:367–73. doi: 10.1097/RLI.00000000000354
- Borggreve AS, Goense L, Brenkman HJF, Mook S, Meijer GJ, Wessels FJ, et al. Imaging Strategies in the Management of Gastric Cancer: Current Role and Future Potential of MRI. *Br J Radiol* (2019) 92:20181044. doi: 10.1259/ bjr.20181044
- Giganti F, Marra P, Ambrosi A, Salerno A, Antunes S, Chiari D, et al. Pre-Treatment MDCT-Based Texture Analysis for Therapy Response Prediction in Gastric Cancer: Comparison With Tumour Regression Grade at Final Histology. *Eur J Radiol* (2017) 90:129–37. doi: 10.1016/j.ejrad.2017.02.043
- Mazzei MA, Nardone V, Di Giacomo L, Bagnacci G, Gentili F, Tini P, et al. The Role of Delta Radiomics in Gastric Cancer. *Quant Imaging Med Surg* (2018) 8:719–21. doi: 10.21037/qims.2018.07.08
- 14. Mazzei MA, Di Giacomo L, Bagnacci G, Nardone V, Gentili F, Lucii G, et al. Delta-Radiomics and Response to Neoadjuvant Treatment in Locally Advanced Gastric Cancer-A Multicenter Study of GIRCG (Italian Research Group for Gastric Cancer). Quant Imaging Med Surg (2021) 11:2376–87. doi: 10.21037/qims-20-683
- 15. Kim HY, Kim YH, Yun G, Chang W, Lee YJ, Kim B. Could Texture Features From Preoperative CT Image be Used for Predicting Occult Peritoneal

## ACKNOWLEDGMENTS

Thanks to our colleague Tian-Wen Xie for assistance with this project and valuable discussion.

# SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022. 821586/full#supplementary-material

Carcinomatosis in Patients With Advanced Gastric Cancer? *PloS One* (2018) 13:e0194755. doi: 10.1371/journal.pone.0194755

- Liu S, He J, Liu S, Ji C, Guan W, Chen L, et al. Radiomics Analysis Using Contrast-Enhanced CT for Preoperative Prediction of Occult Peritoneal Metastasis in Advanced Gastric Cancer. *Eur Radiol* (2020) 30:239–46. doi: 10.1007/s00330-019-06368-5
- Renzulli M, Clemente A, Spinelli D, Ierardi AM, Marasco G, Farina D, et al. Gastric Cancer Staging: Is It Time for Magnetic Resonance Imaging? *Cancers* (*Basel*) (2020) 12:1402. doi: 10.3390/cancers12061402
- Sah BR, Owczarczyk K, Siddique M, Cook GJR, Goh V. Radiomics in Esophageal and Gastric Cancer. *Abdom Radiol (NY)* (2019) 44:2048–58. doi: 10.1007/s00261-018-1724-8
- Liu S, Zhang Y, Xia J, Chen L, Guan W, Guan Y, et al. Predicting the Nodal Status in Gastric Cancers: The Role of Apparent Diffusion Coefficient Histogram Characteristic Analysis. *Magn Reson Imaging* (2017) 42:144–51. doi: 10.1016/j.mri.2017.07.013
- Liu S, Zheng H, Zhang Y, Chen L, Guan W, Guan Y, et al. Whole-Volume Apparent Diffusion Coefficient-Based Entropy Parameters for Assessment of Gastric Cancer Aggressiveness. J Magn Reson Imaging (2018) 47:168–75. doi: 10.1002/jmri.25752
- Zhang Y, Chen J, Liu S, Shi H, Guan W, Ji C, et al. Assessment of Histological Differentiation in Gastric Cancers Using Whole-Volume Histogram Analysis of Apparent Diffusion Coefficient Maps. J Magn Reson Imaging (2017) 45:440–9. doi: 10.1002/jmri.25360
- Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR Imaging of Intravoxel Incoherent Motions: Application to Diffusion and Perfusion in Neurologic Disorders. *Radiology* (1986) 161:401–7. doi: 10.1148/ radiology.161.2.3763909
- Iima M, Le Bihan D. Clinical Intravoxel Incoherent Motion and Diffusion MR Imaging: Past, Present, and Future. *Radiology* (2016) 278:13–32. doi: 10.1148/ radiol.2015150244
- Klauss M, Lemke A, Grünberg K, Simon D, Re TJ, Wente MN, et al. Intravoxel Incoherent Motion MRI for the Differentiation Between Mass Forming Chronic Pancreatitis and Pancreatic Carcinoma. *Invest Radiol* (2011) 46:57– 63. doi: 10.1097/RLI.0b013e3181fb3bf2
- Zuo HD, Zhang XM. Could Intravoxel Incoherent Motion Diffusion-Weighted Magnetic Resonance Imaging be Feasible and Beneficial to the Evaluation of Gastrointestinal Tumors Histopathology and the Therapeutic Response? World J Radiol (2018) 10:116–23. doi: 10.4329/wjr.v10.i10.116
- Just N. Improving Tumour Heterogeneity MRI Assessment With Histograms. Br J Cancer (2014) 111:2205–13. doi: 10.1038/bjc.2014.512
- Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive System. *Lyon: IARC Press* (2010).
- National Health Commission of the People's Republic of China. Notice on the Issuance of "National Standard for Diagnosis and Treatment of Gastric Cancer (2011). Available at: http://www.nhc.gov.cn/wjw/gfxwj/201304/ a70adc50534148448702b9f1ab3abcf7.shtml (Accessed December 31, 2021).
- Zhou D-Y, Zhuang C, Jiao Z-S, Ma J. Step-By-Step Examples of Data Analysis and Statistical Graphs in Clinical Researches. Beijing: Military Med Sci Press (2011). 267 p.
- Salkind NJ. Statistics for People Who (Think They) Hate Statistics. Thousand Oaks CA: SAGE Publications (2016). 480 p.

- 31. Kim HS, Suh CH, Kim N, Choi CG, Kim SJ. Histogram Analysis of Intravoxel Incoherent Motion for Differentiating Recurrent Tumor From Treatment Effect in Patients With Glioblastoma: Initial Clinical Experience. AJNR Am J Neuroradiol (2014) 35:490–7. doi: 10.3174/ajnr.A3719
- 32. Bäuerle T, Seyler L, Münter M, Jensen A, Brand K, Fritzsche KH, et al. Diffusion-Weighted Imaging in Rectal Carcinoma Patients Without and After Chemoradiotherapy: A Comparative Study With Histology. *Eur J Radiol* (2013) 82:444–52. doi: 10.1016/j.ejrad.2012.10.012
- 33. Nougaret S, Vargas HA, Lakhman Y, Sudre R, Do RK, Bibeau F, et al. Intravoxel Incoherent Motion-Derived Histogram Metrics for Assessment of Response After Combined Chemotherapy and Radiation Therapy in Rectal Cancer: Initial Experience and Comparison Between Single-Section and Volumetric Analyses. *Radiology* (2016) 280:446–54. doi: 10.1148/radiol. 2016150702
- 34. Xu Q, Xu Y, Sun H, Chan Q, Shi K, Song A, et al. Quantitative Intravoxel Incoherent Motion Parameters Derived From Whole-Tumor Volume for Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. J Magn Reson Imaging (2018) 48:248–58. doi: 10.1002/jmri.25931
- 35. Sun H, Xu Y, Song A, Shi K, Wang W. Intravoxel Incoherent Motion MRI of Rectal Cancer: Correlation of Diffusion and Perfusion Characteristics With Prognostic Tumor Markers. *AJR Am J Roentgenol* (2018) 210:W139–47. doi: 10.2214/AJR.17.18342
- Song XL, Kang HK, Jeong GW, Ahn KY, Jeong YY, Kang YJ, et al. Intravoxel Incoherent Motion Diffusion-Weighted Imaging for Monitoring Chemotherapeutic Efficacy in Gastric Cancer. World J Gastroenterol (2016) 22:5520–31. doi: 10.3748/wjg.v22.i24.5520
- 37. Cheng J, Wang Y, Zhang CF, Wang H, Wu WZ, Pan F, et al. Chemotherapy Response Evaluation in a Mouse Model of Gastric Cancer Using Intravoxel Incoherent Motion Diffusion-Weighted MRI and Histopathology. World J Gastroenterol (2017) 23:1990–2001. doi: 10.3748/wjg.v23.i11.1990
- Ji C, Chen L, Guan W, Guo T, Zhang Q, Liu S, et al. Intravoxel Incoherent Motion Magnetic Resonance Imaging in Assessing Histopathological Features of Gastric Cancers: Initial Findings. *Transl Cancer Res* (2017) 6:1129–1140. doi: 10.21037/tcr.2017.11.15
- Arai T. Where Does Signet-Ring Cell Carcinoma Come From and Where Does It Go? Gastric Cancer (2019) 22:651–2. doi: 10.1007/s10120-019-00960-w
- 40. Chon HJ, Hyung WJ, Kim C, Park S, Kim JH, Park CH, et al. Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage

Adjusted Analysis From a Single High-Volume Center in Asia. Ann Surg (2017) 265:946–53. doi: 10.1097/SLA.00000000001793

- 41. Kwon CH, Kim YK, Lee S, Kim A, Park HJ, Choi Y, et al. Gastric Poorly Cohesive Carcinoma: A Correlative Study of Mutational Signatures and Prognostic Significance Based on Histopathological Subtypes. *Histopathology* (2018) 72:556–68. doi: 10.1111/his.13383
- 42. Liu S, Guan W, Wang H, Pan L, Zhou Z, Yu H, et al. Apparent Diffusion Coefficient Value of Gastric Cancer by Diffusion-Weighted Imaging: Correlations With the Histological Differentiation and Lauren Classification. *Eur J Radiol* (2014) 83:2122-8. doi: 10.1016/j.ejrad.2014.09.021
- 43. Zhao Q, Xie T, Fu C, Chen L, Bai Q, Grimm R, et al. Differentiation Between Idiopathic Granulomatous Mastitis and Invasive Breast Carcinoma, Both Presenting With Non-Mass Enhancement Without Rim-Enhanced Masses: The Value of Whole-Lesion Histogram and Texture Analysis Using Apparent Diffusion Coefficient. *Eur J Radiol* (2020) 123:108782. doi: 10.1016/ j.ejrad.2019.108782
- Vittinghoff E, McCulloch CE. Relaxing the Rule of Ten Events Per Variable in Logistic and Cox Regression. Am J Epidemiol (2007) 165:710–8. doi: 10.1093/ aje/kwk052

**Conflict of Interest:** C-XF was employed by Siemens Shenzhen Magnetic Resonance Ltd. RG was employed by Siemens Healthcare.

The remaining authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Li, Sun, Tan, Li, Fu, Grimm, Zhu and Peng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.